BrainCool announces two German hospitals, Giesen and Erlangen, are enrolling patients in COTTIS 2 study, aiming to support market approval for RhinoChill® in hypothermic treatment of ischemic stroke patients. The study evaluates neurological function in 400 acute stroke patients treated with hypothermia and thrombectomy. CEO Jon Berg highlights the expansion of patient recruitment and market potential for RhinoChill® System.